Bay Area Life Sciences VC Firm Sofinnova Scores $595.5 Million

Published: Aug 26, 2016

Sofinnova Ventures has raised $595.5 million for its tenth fund, according to an SEC filing. The target is $650 million. The biopharmaceutical venture firm closed its ninth fund at a hard cap of $500 million in July 2014.

Please click here for the SEC Filing.

Back to news